RxDoctor Payments Data

Dilip Desai, PA

Internal Medicine · Linwood, NJNPI 1144213794

Payments from drug & device makers

$434in general payments, 2019–2025

Across 20 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$189
  • AstraZeneca$102
  • GSK$44
  • Pfizer$34
  • Medtronic$25
  • AbbVie$14
  • plus $26 from 2 others

What the payments were for

  • Food & beverage$434100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead10$189
AstraZeneca1$102
GSK3$44
Pfizer2$34
Medtronic1$25
AbbVie1$14
Novo Nordisk1$14
Novartis1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$434 in reported general payments places this provider in the 50th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$586,031
Medicare patients
1,278
Services billed
6,761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban118$138,026
JanuviaSitagliptin Phosphate70$75,436
FarxigaDapagliflozin Propanediol70$71,448
JardianceEmpagliflozin22$27,996
OzempicSemaglutide17$27,141
XareltoRivaroxaban25$22,109
EntrestoSacubitril/Valsartan12$18,134
TrulicityDulaglutide11$10,565
MyrbetriqMirabegron11$10,554
JanumetSitagliptin Phos/Metformin Hcl12$10,080
Repatha SureclickEvolocumab13$9,239
Rosuvastatin Calcium382$5,580
Breo ElliptaFluticasone/Vilanterol13$5,225
Atorvastatin Calcium420$4,405
Losartan Potassium365$4,035

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$138,026118 claims
AstraZenecaFarxiga$102$71,44870 claims
Novo NordiskOzempic$14$27,14117 claims
NovartisEntresto$13$18,13412 claims
GSKBreo Ellipta$44$5,22513 claims
AbbVieSynthroid$14$3,46160 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Linwood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →